
    
      The clinical efficacy and safety of Nonafact® has been shown in two pre-authorisation
      studies. Marketing authorisation for the EU was granted 3 July 2001. The Post Marketing
      Study, which evaluates the clinical efficacy, immunogenicity and safety of Nonafact®, is set
      up according to CPMP/BPWG /198/95, rev. 1 (Final, London, 19 October 2000) 'Note for guidance
      on the clinical investigation of human plasma derived factor VIII and IX products'
    
  